Success of OncoTherm

Dr. Oliver Szasz¹

(1) Oncotherm Group, Germany (Dr.Szasz@oncotherm.de)
Success of OncoTherm
Dr. Oliver Szasz
(1) Oncotherm Group, Germany Dr.Szasz@oncotherm.de

Background: Oncotherm has started its life in the Universities. The ideas were formulated as a part of the surface science in Glasgow (Scottish Surface Centre, Strathclyde University), followed by a spin-off from the Eotvos University Budapest in 1988. The first contacts with Germany were established almost immediately. Dr. Douwes (St.Georg Klinik, Bad Aibling), asked the clinical use of the till that time only theoretically formulated ideas. The actual requests of the clinical use formulated by Dr. Douwes were successfully performed, starting with galvano-therapies, and continuing to the basic of the presently well known oncothermia method. The company is certified in all aspects by the rigorous German TUV services having the CE and the ISO approvals for the products and production processes, respectively.

Results: Oncothermia became a known therapy worldwide. Its results are beneficial and popular in every places where it is applied. Presently oncothermia is present in 21 countries, and our production was 262 devices in the time of existence. From this we have active contacts with 200 devices in 17 countries. During our existence we have developed different devices in seven categories: shallow local (ECT, ICT, Surface), intraluminar (PCT, EHY1000, EHY1020), loco-regional (EHY2000, EHY2000+, EHY2010, REY), multi-local (EHY3000 series), whole body (WBH, MSH), laboratory devices (LabEHY, EHYS110) and other devices (Booster and Androtherm). Having ... devices in work and developed transurethral (EHY1000 series), local and regional (EHY2000 series) and multi-local (EHY3000 series) treatments and their devices.

Presently our Oncotherm Company works now on entire brand new concepts (OTD devices) and developing huge number of new scientific projects and ideas. The actually working devices perform more than 100.000 treatments yearly in the market, and no any safety problem was arisen till now. Our philosophy is based on 3E+3S concept:

3E: 1. efficacy by large energy-absorption with electric field assistance, 2. efficacy by cellular self-selective focus realized by modulated RF-current, 3. efficacy by distinct improvement of the survival rate and by unambiguous increase of the quality of life

3S: 1. safety for the patient with optimally personalized energy-absorption, based on the enduring control of the RF current through the patient 2. safety for the treating medical personnel with high electromagnetic standards, making possible to use oncothermia even in dwelling-houses, 3. safety for your quiet daily work by the solid scientific, biomedical and clinical proofs.

Conclusions: Oncothermia opened new dimensions in hyperthermic oncology. We are proud, that the modern technical solutions and the "Med-in-Garmany" medical practice had such a synergy which has changed the 2000 years old paradigm and made the hyperthermia ready to be accepted widely by the medical communities.